CR Bard (NYSE: BCR ) is expected to report Q4 earnings on Jan. 31. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict CR Bard's revenues will grow 0.8% and EPS will wither -1.8%.
The average estimate for revenue is $757.9 million. On the bottom line, the average EPS estimate is $1.67.
Last quarter, CR Bard reported revenue of $722.9 million. GAAP reported sales were 0.5% higher than the prior-year quarter's $719.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.64. GAAP EPS of $1.50 for Q3 were 2.7% higher than the prior-year quarter's $1.46 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 62.3%, 50 basis points better than the prior-year quarter. Operating margin was 27.9%, 100 basis points worse than the prior-year quarter. Net margin was 17.9%, 20 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $2.96 billion. The average EPS estimate is $6.54.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 265 members out of 274 rating the stock outperform, and nine members rating it underperform. Among 104 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 102 give CR Bard a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CR Bard is hold, with an average price target of $105.21.
Is CR Bard the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.